Created at	Source	Raw Value	Validated value
June 24, 2022, 9 p.m.	usa	Non-inferiority, or superiority in terms of neutralizing antibodies against the SARS-CoV-2 index virus (Wuhan wild type isolate), in Part A Cohort 1 and 2	Non-inferiority, or superiority in terms of neutralizing antibodies against the SARS-CoV-2 index virus (Wuhan wild type isolate), in Part A Cohort 1 and 2
April 15, 2022, 11:30 p.m.	usa	Non-inferiority in terms of neutralizing antibodies against the original (Wuhan) SARS-CoV-2	Non-inferiority in terms of neutralizing antibodies against the original (Wuhan) SARS-CoV-2